Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daigo Hashimoto

Showing results (121-130 of 127) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 127 results.
Annals of Hematology|November 30, 2024
FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AMLToshihiro Matsukawa, Masahiro Onozawa, Takeshi Kondo, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 8, 2018
Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net StudyDaisuke Hidaka, Masahiro Onozawa, Junichi Hashiguchi, et al.
Eclinicalmedicine|February 19, 2025
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trialKazuyuki Shimada, Motoko Yamaguchi, Yachiyo Kuwatsuka, et al.
The Lancet. Oncology|March 15, 2020
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trialKazuyuki Shimada, Motoko Yamaguchi, Yoshiko Atsuta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell TransplantationRoni Shouval, Nicholas R Waters, Antonio L C Gomes, et al.
Blood Advances|August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN StudyNirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
The New England Journal of Medicine|February 27, 2020
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell TransplantationJonathan U Peled, Antonio L C Gomes, Sean M Devlin, et al.
Pageof 13

Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
Annals of Hematology|November 30, 2024
FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AMLToshihiro Matsukawa, Masahiro Onozawa, Takeshi Kondo, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 8, 2018
Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net StudyDaisuke Hidaka, Masahiro Onozawa, Junichi Hashiguchi, et al.
Eclinicalmedicine|February 19, 2025
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trialKazuyuki Shimada, Motoko Yamaguchi, Yachiyo Kuwatsuka, et al.
The Lancet. Oncology|March 15, 2020
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trialKazuyuki Shimada, Motoko Yamaguchi, Yoshiko Atsuta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell TransplantationRoni Shouval, Nicholas R Waters, Antonio L C Gomes, et al.
Blood Advances|August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN StudyNirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
The New England Journal of Medicine|February 27, 2020
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell TransplantationJonathan U Peled, Antonio L C Gomes, Sean M Devlin, et al.
Pageof 13